– A non-dilutive financing facility plus $312 million of existing cash as of June 30, 2022 gives atai access to up to $487 million to continue developing next-generation mental health treatments

– The flexible drawing availability offers the opportunity to optimize liquidity and capital structure in the future

NEW YORK and BERLIN, August 15, 2022 (GLOBE NEWSWIRE) — atai Life Sciences NV ATAI (“atai”), a clinical-stage biopharmaceutical company committed to transforming the treatment of mental disorders, announced today that it has joined forces with Hercules Capital, Inc. HTGC.

“The non-dilutive capital from this term loan facility, combined with the cash already on our balance sheet, further strengthens atai’s financial strength and provides us with strategic flexibility in building a leading mental health company dedicated to addressing the significant unfunded patient needs in neuropsychiatry. said Florian Brand, Chief Executive Officer and co-founder of atai. “As we continue to execute our diversified pipeline of differentiated drug candidates, we look forward to several anticipated near-term catalysts in our key programs, including PCN-101’s Phase 2a data in treatment-resistant depression later this year. “

“Hercules is excited to partner with atai as it advances a pipeline of novel assets designed to bring new treatment options to patients with mental disorders,” said Janice Bourque, Managing Director at Hercules Capital. “Hercules’ significant commitment is designed to help atai fulfill its important mission and reflects our commitment to funding innovative life science companies,” added Michael Dutra, Managing Director at Hercules Capital.

Under the terms of the $175 million loan facility, $15 million was drawn at closing, with an additional $20 million to be drawn at atai’s option by May 15.